Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | PTEN | P60484 | 1/20 | 0.33 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11254152 | 0.72 | KEAP1 (0.36) | KEAP1FFAR1NPSR1ALDH1A1POLB | |
| SCHEMBL13149371 | 0.72 | NPSR1 (0.35) | KEAP1FFAR1NPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10280445 | 0.71 | KEAP1 (0.35) | KEAP1FFAR1NPSR1ALDH1A1HSD17B10 | |
| SCHEMBL8242961 | 0.71 | HDAC1 (0.41) | FFAR1MAPTHSD17B10HDAC3MAPK1 | |
| SCHEMBL6093157 | 0.69 | KEAP1 (0.34) | KEAP1FFAR1NPSR1ALDH1A1HSD17B10 | |
| SCHEMBL7283235 | 0.68 | KEAP1 (0.33) | KEAP1FFAR1NPSR1FFAR4 | |
| SCHEMBL7413999 | 0.67 | ALDH1A1 (0.33) | KEAP1FFAR1NPSR1ALDH1A1POLB | |
| SCHEMBL238692 | 0.66 | — | — | |
| SCHEMBL2147545 | 0.64 | — | — | |
| SCHEMBL69746 | 0.59 | FFAR1 (0.81) | KEAP1FFAR1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-15 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-110650947-B | Methods and molecules | 免疫医疗有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
| EP-3630732-A1 | METHOD AND MOLECULES | Medimmune, LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110650947-A | Methods and molecules | 免疫医疗有限责任公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2018218093-A1 | METHOD AND MOLECULES | MEDIMMUNE, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | PAICS, EPCAM, SQLE | KEAP1 249/4885FFAR1 175/4885NPSR1 271/4885 |
| US-20200206359-A1 | Method And Molecules | PAICS, EPCAM, SQLE | KEAP1 249/4885FFAR1 175/4885NPSR1 271/4885 |
| US-20230321267-A1 | Method And Molecules | PAICS, EPCAM, SQLE | KEAP1 249/4885FFAR1 175/4885NPSR1 271/4885 |
| US-11759526-B2 | Method and molecules | PAICS, EPCAM, SQLE | KEAP1 249/4885FFAR1 175/4885NPSR1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.